ID   92-13
AC   CVCL_C6NG
DR   Wikidata; Q116048433
RX   Patent=US9139655;
RX   PubMed=18271942;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10628.
CC   Biotechnology: When radiolabeled with Yttrium-90 the monoclonal antibody produced by this hybridoma can be used for the treatment of synovial sarcomas.
CC   Monoclonal antibody isotype: IgG2a.
CC   Monoclonal antibody target: UniProtKB; Q9ULW2; Human FZD10.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 15-12-22; Last updated: 21-03-23; Version: 2
//
RX   Patent=US9139655;
RA   Nakamura Y., Katagiri T., Nakatsuru S., Endo K., Kuhara M., Yagi K.;
RT   "Tumor-targeting monoclonal antibodies to FZD10 and uses thereof.";
RL   Patent number US9139655, 22-Sep-2015.
//
RX   PubMed=18271942; DOI=10.1111/j.1349-7006.2007.00701.x;
RA   Fukukawa C., Hanaoka H., Nagayama S., Tsunoda T., Toguchida J.,
RA   Endo K., Nakamura Y., Katagiri T.;
RT   "Radioimmunotherapy of human synovial sarcoma using a monoclonal
RT   antibody against FZD10.";
RL   Cancer Sci. 99:432-440(2008).
//